Gabriel Caruso Novaes Tudella
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Gabriel Caruso Novaes Tudella has a total of 117 co-authors. Here are the top co-authors by number of shared publications:
- Ocílio Ribeiro Gonçalves
Federal University of Piaui
4 shared publications - Anderson Matheus Pereira da Silva
Department of Physiology and Pharmacology, Federal University of Pernambuco, Recife, Brazil
3 shared publications - Ahmet Günkan
Department of Radiology and Imaging Sciences, Division of Interventional Radiology, University of Arizona Medical Center, Tucson, USA
2 shared publications Anderson Matheus Pereira da Silva
Department of Clinical Research, Division of Biostatistics and Clinical Epidemiology, MemoryHub, Cognitive and Neurodegenerative Disorders Research Group, São Paulo
2 shared publicationsAugusto Utida Klostermann
Department of Medicine, Federal University of Santa Maria, Santa Maria, Brazil
2 shared publications- Augusto Utida Klostermann
Department of Medicine, Federal University of Santa Maria, Brazil
2 shared publications
Latest Publications
- Open Access
- 29 August 2026
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 142, 212-219
Late-onset unprovoked seizures and subsequent risk of dementia in older adults: A target trial emulation
- 29 August 2026
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 142, 212-219
Open AccessLate-onset unprovoked seizures and subsequent risk of dementia in older adults: A target trial emulation
- 1 August 2026
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 16 (4) , e200636
Efficacy and Safety of Perampanel in Patients With Brain Tumor-Related Epilepsy
Epileptic seizures are a common and often debilitating complication in patients with brain tumors, significantly affecting quality of life and clinical outcomes. Brain tumor-related epilepsy (BTRE) is characterized by complex pathophysiologic mechanisms, notably glutamate-mediated neuronal hyperexcitability within the peritumoral environment. Perampanel, a selective, noncompetitive antagonist of the AMPA glutamate receptor, represents a mechanistically targeted antiseizure medication that may be particularly suited to this context. This review aims to systematically evaluate and synthesize the available evidence regarding the efficacy and safety of perampanel in patients with BTRE, focusing on seizure control, oncologic outcomes, and tolerability in real-world clinical settings. A systematic search of PubMed, Embase, and Cochrane Library identified 8 observational studies involving a total of 382 patients with brain tumors and associated seizures treated with perampanel. Across studies, 57.0% of patients were male, and the mean participant age ranged from 43 to 58 years. Pooled analyses demonstrated that 42% (95% CI 27%-59%) of patients achieved seizure freedom, while 46% (95% CI 31%-61%) experienced a ≥50% reduction in seizure frequency. Oncological progression was reported in 39% (95% CI 17%-65%) of patients, with no evidence of perampanel effect on tumor behavior. Adverse events occurred in 26% (95% CI 17%-38%) of patients, most of which were mild to moderate and consistent with the known safety profile of perampanel. Perampanel is associated with meaningful seizure control in a substantial proportion of patients with brain tumor-related epilepsy, including high rates of seizure freedom and significant seizure reduction. Importantly, its use does not appear to influence oncologic progression nor substantially increase the incidence of adverse events. Although limited by the nonrandomized nature of the available studies, these findings support perampanel as a valuable therapeutic option for symptomatic seizure management in BTRE, with potential utility in both adjunctive treatment strategies and palliative care settings. Further prospective and controlled studies are warranted to better define its optimal role and long-term impact in this complex patient population.
- 1 August 2026
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 16 (4) , e200636
Efficacy and Safety of Perampanel in Patients With Brain Tumor-Related Epilepsy
Epileptic seizures are a common and often debilitating complication in patients with brain tumors, significantly affecting quality of life and clinical outcomes. Brain tumor-related epilepsy (BTRE) is characterized by complex pathophysiologic mechanisms, notably glutamate-mediated neuronal hyperexcitability within the peritumoral environment. Perampanel, a selective, noncompetitive antagonist of the AMPA glutamate receptor, represents a mechanistically targeted antiseizure medication that may be particularly suited to this context. This review aims to systematically evaluate and synthesize the available evidence regarding the efficacy and safety of perampanel in patients with BTRE, focusing on seizure control, oncologic outcomes, and tolerability in real-world clinical settings. A systematic search of PubMed, Embase, and Cochrane Library identified 8 observational studies involving a total of 382 patients with brain tumors and associated seizures treated with perampanel. Across studies, 57.0% of patients were male, and the mean participant age ranged from 43 to 58 years. Pooled analyses demonstrated that 42% (95% CI 27%-59%) of patients achieved seizure freedom, while 46% (95% CI 31%-61%) experienced a ≥50% reduction in seizure frequency. Oncological progression was reported in 39% (95% CI 17%-65%) of patients, with no evidence of perampanel effect on tumor behavior. Adverse events occurred in 26% (95% CI 17%-38%) of patients, most of which were mild to moderate and consistent with the known safety profile of perampanel. Perampanel is associated with meaningful seizure control in a substantial proportion of patients with brain tumor-related epilepsy, including high rates of seizure freedom and significant seizure reduction. Importantly, its use does not appear to influence oncologic progression nor substantially increase the incidence of adverse events. Although limited by the nonrandomized nature of the available studies, these findings support perampanel as a valuable therapeutic option for symptomatic seizure management in BTRE, with potential utility in both adjunctive treatment strategies and palliative care settings. Further prospective and controlled studies are warranted to better define its optimal role and long-term impact in this complex patient population.
- 31 July 2026
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
Efficacy and Safety of Alpha-Lipoic Acid as an Adjunctive Therapy in Schizophrenia
Background: Alpha-lipoic acid (ALA) is an antioxidant proposed to mitigate metabolic burden and psychopathology in schizophrenia. We systematically reviewed the efficacy and safety of ALA as an adjunct to antipsychotics. Methods: We searched MEDLINE, Embase, and the Cochrane Library from inception to September 2025 for human studies evaluating ALA in individuals with schizophrenia. Random-effects meta-analyses pooled mean differences (MDs) with 95% CIs for continuous outcomes and pooled proportions for adverse events and discontinuation. Results: Eight studies (n = 165) were included. In single-arm analyses, ALA showed no significant improvements in PANSS scores in pooled estimates, despite isolated findings in small subsets. A reduction in BMI was observed in the RCT subgroup but not in the overall analysis. No significant effects were found for HbA1c, waist circumference, or lipid profile. In ALA versus placebo comparisons, no significant differences were observed for PANSS scores, BMI, adverse events, or discontinuation. ALA was generally well tolerated, though findings were limited by small sample sizes and imprecision. Conclusions: Current evidence suggests adjunctive ALA may modestly influence selected PANSS subscales but does not improve metabolic outcomes. Larger, well-designed trials with standardized dosing and longer follow-up are needed to clarify clinical relevance and safety.
- 31 July 2026
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
Efficacy and Safety of Alpha-Lipoic Acid as an Adjunctive Therapy in Schizophrenia
Background: Alpha-lipoic acid (ALA) is an antioxidant proposed to mitigate metabolic burden and psychopathology in schizophrenia. We systematically reviewed the efficacy and safety of ALA as an adjunct to antipsychotics. Methods: We searched MEDLINE, Embase, and the Cochrane Library from inception to September 2025 for human studies evaluating ALA in individuals with schizophrenia. Random-effects meta-analyses pooled mean differences (MDs) with 95% CIs for continuous outcomes and pooled proportions for adverse events and discontinuation. Results: Eight studies (n = 165) were included. In single-arm analyses, ALA showed no significant improvements in PANSS scores in pooled estimates, despite isolated findings in small subsets. A reduction in BMI was observed in the RCT subgroup but not in the overall analysis. No significant effects were found for HbA1c, waist circumference, or lipid profile. In ALA versus placebo comparisons, no significant differences were observed for PANSS scores, BMI, adverse events, or discontinuation. ALA was generally well tolerated, though findings were limited by small sample sizes and imprecision. Conclusions: Current evidence suggests adjunctive ALA may modestly influence selected PANSS subscales but does not improve metabolic outcomes. Larger, well-designed trials with standardized dosing and longer follow-up are needed to clarify clinical relevance and safety.
- 14 July 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (1) , e218175
Fecal Microbiota Transplantation in Parkinson Disease
Background and ObjectivesParkinson disease (PD) is a progressive neurodegenerative disorder increasingly linked to gut microbiota dysbiosis, which may influence disease mechanisms and symptom expre...
- 14 July 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (1) , e218175
Fecal Microbiota Transplantation in Parkinson Disease
Background and ObjectivesParkinson disease (PD) is a progressive neurodegenerative disorder increasingly linked to gut microbiota dysbiosis, which may influence disease mechanisms and symptom expre...
- 29 June 2026
- Published by Springer Nature in Clinical Neuroradiology
- p. 1-17
Magnetic Resonance Imaging/Diffusion-Weighted Imaging-Guided Versus Perfusion-Guided Intravenous Thrombolysis with Alteplase Beyond 4.5-Hour Window: a Network Meta-Analysis of Randomized Controlled Trials
Background The benefits and risks of intravenous thrombolysis (IVT) with alteplase for acute ischemic stroke (AIS) beyond 4.5 h are unclear. Decision-making is further limited by the lack of comparisons between imaging strategies used for patient selection, including magnetic resonance imaging with diffusion-weighted imaging (MRI/DWI) and perfusion-guided approaches such as MRI with perfusion-weighted imaging (MRI/PWI) or computed tomography perfusion (CTP). This study aims to evaluate the efficacy and safety of alteplase administered beyond 4.5 h and to compare MRI/DWI- and perfusion-guided IVT. Methods Databases were searched for RCTs enrolling AIS patients treated with alteplase beyond 4.5 h. Efficacy outcomes included excellent (mRS 0–1) and favorable (mRS 0–2) functional outcomes at 90 days, and major neurological improvement up to 72 h. Safety outcomes included any intracranial hemorrhage (aICH), symptomatic ICH (sICH), parenchymal hemorrhage (PH), and 90-day mortality. Results Seven RCTs comprising 1685 patients were included. There were no differences between imaging strategies in any efficacy or safety outcome. Alteplase administered beyond 4.5 h was associated with higher rates of excellent (RR 1.24; 95% CI 1.12–1.38) and favorable (RR 1.17; 95% CI 1.09–1.26) functional outcomes, and increased major neurological improvement (RR 1.28; 95% CI 1.11–1.49). The risks of aICH (RR, 2.82; 95% CI 1.17–6.80), sICH (RR, 3.31; 95% CI 1.42–7.74), and PH (RR, 2.95; CI 95% 1.33–6.53) were higher in the alteplase group, while mortality showed no difference (RR 1.27; 95% CI 0.91–1.76). Conclusion This network meta-analysis did not detect a statistically significant difference between perfusion-guided and DWI/FLAIR mismatch–guided selection; however, this comparison was indirect, based on a limited number of trials, and not powered to demonstrate equivalence, and should not be interpreted as evidence that the two paradigms are interchangeable.
- 29 June 2026
- Published by Springer Nature in Clinical Neuroradiology
- p. 1-17
Magnetic Resonance Imaging/Diffusion-Weighted Imaging-Guided Versus Perfusion-Guided Intravenous Thrombolysis with Alteplase Beyond 4.5-Hour Window: a Network Meta-Analysis of Randomized Controlled Trials
Background The benefits and risks of intravenous thrombolysis (IVT) with alteplase for acute ischemic stroke (AIS) beyond 4.5 h are unclear. Decision-making is further limited by the lack of comparisons between imaging strategies used for patient selection, including magnetic resonance imaging with diffusion-weighted imaging (MRI/DWI) and perfusion-guided approaches such as MRI with perfusion-weighted imaging (MRI/PWI) or computed tomography perfusion (CTP). This study aims to evaluate the efficacy and safety of alteplase administered beyond 4.5 h and to compare MRI/DWI- and perfusion-guided IVT. Methods Databases were searched for RCTs enrolling AIS patients treated with alteplase beyond 4.5 h. Efficacy outcomes included excellent (mRS 0–1) and favorable (mRS 0–2) functional outcomes at 90 days, and major neurological improvement up to 72 h. Safety outcomes included any intracranial hemorrhage (aICH), symptomatic ICH (sICH), parenchymal hemorrhage (PH), and 90-day mortality. Results Seven RCTs comprising 1685 patients were included. There were no differences between imaging strategies in any efficacy or safety outcome. Alteplase administered beyond 4.5 h was associated with higher rates of excellent (RR 1.24; 95% CI 1.12–1.38) and favorable (RR 1.17; 95% CI 1.09–1.26) functional outcomes, and increased major neurological improvement (RR 1.28; 95% CI 1.11–1.49). The risks of aICH (RR, 2.82; 95% CI 1.17–6.80), sICH (RR, 3.31; 95% CI 1.42–7.74), and PH (RR, 2.95; CI 95% 1.33–6.53) were higher in the alteplase group, while mortality showed no difference (RR 1.27; 95% CI 0.91–1.76). Conclusion This network meta-analysis did not detect a statistically significant difference between perfusion-guided and DWI/FLAIR mismatch–guided selection; however, this comparison was indirect, based on a limited number of trials, and not powered to demonstrate equivalence, and should not be interpreted as evidence that the two paradigms are interchangeable.
- 16 June 2026
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 112 (3) , 1143-1158
Impacts of menopausal hormone therapy on Alzheimer's disease biomarkers: A systematic review
Background: Sex-specific vulnerability to Alzheimer's disease (AD) has been increasingly recognized, with menopause representing a decisive neuroendocrine transition. Estrogen and progesterone modulate synaptic plasticity, glucose metabolism, and amyloid-tau homeostasis, yet the impact of their decline and replacement remains controversial. AD biomarkers provide objective means to assess menopausal hormone therapy (MHT) mechanistic effects beyond cognitive endpoints. Objective: To determine how MHT influences validated AD biomarkers in peri- and postmenopausal women. Methods: A systematic review was conducted following PRISMA guidelines (PROSPERO CRD420251149404). PubMed, Embase, Web of Science, and Cochrane Library were searched through September 2025 for interventional and observational studies evaluating MHT and AD biomarkers after non-surgical menopause. Eligible biomarkers included cerebrospinal fluid (CSF) and plasma markers, and amyloid-, tau- or FDG-PET imaging. Study quality was assessed using RoB-2 and ROBINS-I tools, and evidence certainty with GRADE. Results: Fourteen studies met inclusion criteria. Early or continuous transdermal 17β-estradiol was linked with lower CSF and plasma p-tau181 and preserved glucose metabolism in AD-vulnerable cortical regions. Neuroimaging studies showed decreased amyloid deposition and sustained metabolic benefits years after discontinuation. Conversely, oral conjugated equine estrogens and estrogen-progestin regimens led to neutral or unfavorable biomarker trends, particularly when initiated more than five years after menopause. Conclusions: MHT's effects on AD biomarkers depend on timing, formulation and hormonal composition. Early transdermal estradiol appears to reinforce neuroprotective biomarker profiles, whereas delayed or combined therapies may nullify these benefits. Genotype-stratified trials with harmonized biomarker reports are needed to define optimal neuroprotective windows for women.
- 16 June 2026
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 112 (3) , 1143-1158
Impacts of menopausal hormone therapy on Alzheimer's disease biomarkers: A systematic review
Background: Sex-specific vulnerability to Alzheimer's disease (AD) has been increasingly recognized, with menopause representing a decisive neuroendocrine transition. Estrogen and progesterone modulate synaptic plasticity, glucose metabolism, and amyloid-tau homeostasis, yet the impact of their decline and replacement remains controversial. AD biomarkers provide objective means to assess menopausal hormone therapy (MHT) mechanistic effects beyond cognitive endpoints. Objective: To determine how MHT influences validated AD biomarkers in peri- and postmenopausal women. Methods: A systematic review was conducted following PRISMA guidelines (PROSPERO CRD420251149404). PubMed, Embase, Web of Science, and Cochrane Library were searched through September 2025 for interventional and observational studies evaluating MHT and AD biomarkers after non-surgical menopause. Eligible biomarkers included cerebrospinal fluid (CSF) and plasma markers, and amyloid-, tau- or FDG-PET imaging. Study quality was assessed using RoB-2 and ROBINS-I tools, and evidence certainty with GRADE. Results: Fourteen studies met inclusion criteria. Early or continuous transdermal 17β-estradiol was linked with lower CSF and plasma p-tau181 and preserved glucose metabolism in AD-vulnerable cortical regions. Neuroimaging studies showed decreased amyloid deposition and sustained metabolic benefits years after discontinuation. Conversely, oral conjugated equine estrogens and estrogen-progestin regimens led to neutral or unfavorable biomarker trends, particularly when initiated more than five years after menopause. Conclusions: MHT's effects on AD biomarkers depend on timing, formulation and hormonal composition. Early transdermal estradiol appears to reinforce neuroprotective biomarker profiles, whereas delayed or combined therapies may nullify these benefits. Genotype-stratified trials with harmonized biomarker reports are needed to define optimal neuroprotective windows for women.
- Open Access
- 6 June 2026
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 28 (11) , 5570-5580
Is tattooing associated with an increased risk of cancer? A systematic review and meta-analysis
Background: Tattoo inks may contain carcinogenic compounds, and pigment migration to lymphatic tissues raises concerns regarding potential cancer risk. Epidemiological evidence remains inconclusive. Objectives: To assess the association between tattoo exposure and the incidence of skin cancer and hematological malignancies. Methods: PubMed, Embase, and the Cochrane Library were searched from inception to January 2026 for cohort and case–control studies comparing cancer incidence in tattooed versus non-tattooed adults. Random-effects meta-analyses using restricted maximum-likelihood estimators were performed to pool odds ratios (ORs) with 95% confidence intervals (CIs). Heterogeneity was quantified using I 2 statistics. Risk of bias was assessed using ROBINS-E, and certainty of evidence was evaluated with GRADE. Leave-one-out sensitivity analyses were conducted. Results: Seven observational studies including 140,841 participants were analyzed. Tattoo exposure was not associated with overall skin cancer (OR 0.92; 95%CI 0.83–1.04; I 2 = 0%; p = 0.179). Stratified analyses by number of tattoo sessions showed no significant associations: one session (OR 1.08; 95%CI 0.55–2.12; I 2 = 92.4%), two-to-three sessions (OR 0.90; 95%CI 0.62–1.32; I 2 = 63.2%), and ≥ 4 sessions (OR 0.70; 95%CI 0.29–1.70; I 2 = 88.5%). For hematological malignancies, pooled analysis showed no significant association (OR 1.02; 95%CI 0.78–1.32; I 2 = 64.9%; p = 0.910). Subtype analyses were non-significant: non-Hodgkin lymphoma (OR 1.00; 95%CI 0.73–1.36; I 2 = 3.7%), Hodgkin lymphoma (OR 1.19; 95%CI 0.59–2.40; I 2 = 91.7%), diffuse large B-cell lymphoma (OR 0.90; 95%CI 0.57–1.44; I 2 = 61.7%), T-cell lymphoma (OR 1.07; 95%CI 0.61–1.88; I 2 = 0%), and follicular lymphoma (OR 0.99; 95%CI 0.72–1.36; I 2 = 1.9%). Sensitivity analysis excluding one influential study rendered the association for overall hematological malignancies statistically significant (OR 1.20; 95%CI 1.05–1.39; I 2 = 0%). Certainty of evidence ranged from low to moderate. Conclusions: Tattoo exposure was not associated with increased skin cancer risk and showed no significant association with hematological malignancies in primary analyses. A significant association emerged only after sensitivity analysis, warranting cautious interpretation and further prospective investigation.
- 6 June 2026
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 28 (11) , 5570-5580
Open AccessIs tattooing associated with an increased risk of cancer? A systematic review and meta-analysis
Background: Tattoo inks may contain carcinogenic compounds, and pigment migration to lymphatic tissues raises concerns regarding potential cancer risk. Epidemiological evidence remains inconclusive. Objectives: To assess the association between tattoo exposure and the incidence of skin cancer and hematological malignancies. Methods: PubMed, Embase, and the Cochrane Library were searched from inception to January 2026 for cohort and case–control studies comparing cancer incidence in tattooed versus non-tattooed adults. Random-effects meta-analyses using restricted maximum-likelihood estimators were performed to pool odds ratios (ORs) with 95% confidence intervals (CIs). Heterogeneity was quantified using I 2 statistics. Risk of bias was assessed using ROBINS-E, and certainty of evidence was evaluated with GRADE. Leave-one-out sensitivity analyses were conducted. Results: Seven observational studies including 140,841 participants were analyzed. Tattoo exposure was not associated with overall skin cancer (OR 0.92; 95%CI 0.83–1.04; I 2 = 0%; p = 0.179). Stratified analyses by number of tattoo sessions showed no significant associations: one session (OR 1.08; 95%CI 0.55–2.12; I 2 = 92.4%), two-to-three sessions (OR 0.90; 95%CI 0.62–1.32; I 2 = 63.2%), and ≥ 4 sessions (OR 0.70; 95%CI 0.29–1.70; I 2 = 88.5%). For hematological malignancies, pooled analysis showed no significant association (OR 1.02; 95%CI 0.78–1.32; I 2 = 64.9%; p = 0.910). Subtype analyses were non-significant: non-Hodgkin lymphoma (OR 1.00; 95%CI 0.73–1.36; I 2 = 3.7%), Hodgkin lymphoma (OR 1.19; 95%CI 0.59–2.40; I 2 = 91.7%), diffuse large B-cell lymphoma (OR 0.90; 95%CI 0.57–1.44; I 2 = 61.7%), T-cell lymphoma (OR 1.07; 95%CI 0.61–1.88; I 2 = 0%), and follicular lymphoma (OR 0.99; 95%CI 0.72–1.36; I 2 = 1.9%). Sensitivity analysis excluding one influential study rendered the association for overall hematological malignancies statistically significant (OR 1.20; 95%CI 1.05–1.39; I 2 = 0%). Certainty of evidence ranged from low to moderate. Conclusions: Tattoo exposure was not associated with increased skin cancer risk and showed no significant association with hematological malignancies in primary analyses. A significant association emerged only after sensitivity analysis, warranting cautious interpretation and further prospective investigation.
- 1 April 2026
- Published by Springer Nature in Neurological Sciences
- Vol. 47 (4) , 394
Patent foramen ovale closure versus medical therapy alone in elderly patients with cryptogenic stroke: a systematic review and meta-analysis
- 1 April 2026
- Published by Springer Nature in Neurological Sciences
- Vol. 47 (4) , 394
Patent foramen ovale closure versus medical therapy alone in elderly patients with cryptogenic stroke: a systematic review and meta-analysis
- 29 March 2026
- Published by Elsevier in Acta Tropica
- Vol. 278, 108077
Malaria and Chagas disease in non-endemic settings in Brazil: a comparative analysis of national surveillance data (2007–2024)
- 29 March 2026
- Published by Elsevier in Acta Tropica
- Vol. 278, 108077
Malaria and Chagas disease in non-endemic settings in Brazil: a comparative analysis of national surveillance data (2007–2024)
- 3 March 2026
- Published by Taylor & Francis in Neurological Research
- p. 1-14
Tenecteplase versus alteplase as bridging therapy before endovascular treatment in acute ischemic stroke due to Basilar artery occlusion: a systematic review and meta-analysis
Basilar artery occlusion (BAO) is a rare but highly morbid subtype of acute ischemic stroke, representing approximately 1% of all ischemic events and associated with substantial risks of long-term ...
- 3 March 2026
- Published by Taylor & Francis in Neurological Research
- p. 1-14
Tenecteplase versus alteplase as bridging therapy before endovascular treatment in acute ischemic stroke due to Basilar artery occlusion: a systematic review and meta-analysis
Basilar artery occlusion (BAO) is a rare but highly morbid subtype of acute ischemic stroke, representing approximately 1% of all ischemic events and associated with substantial risks of long-term ...